Avacta Therapeutics to Sell UK Diagnostics Unit for GBP13 Million

Published on 07/03/2025 at 16:42 - Modified on 07/03/2025 at 17:03

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Avacta Group Plc

Avacta Group Raises GBP3 Million via Share Placement Offer	17/07	MT
Avacta announces equity fundraise of £3.25 mln	17/07	RE
Avacta Group Plc - Shareholder/Analyst Call	15/07
IntelliAM wins order; Schroder BSC mulls options	03/07	AN
EXECUTIVE CHANGES: Avacta names CMO, Mission Group appoints CEO	02/07	AN
Avacta Group Names Chief Medical Officer	01/07	MT
Avacta Group plc Appoints David Liebowitz as Chief Medical Officer	01/07	CI
Avacta Group plc Announces New Response in the FAP-Dox Phase 1B Trial	19/06	CI
Journeo in New York deal; Anpario to meet market view	19/06	AN
Avacta Group Announces New Partial Response In FAP-Dox Phase 1b Trial	19/06	RE
Avacta Group Plc - Special Call	11/06
Avacta Group Plc, 2024 Earnings Call, Jun 06, 2025	07/06
Avacta revenue falls, sees "transformative" year after repositioning	06/06	AN
Avacta Therapeutics Says FAP-Dox Initial Data In Salivary Gland Cancer Expected Late 2025	06/06	RE
Avacta Group Plc Reports Earnings Results for the Full Year Ended December 31, 2024	06/06	CI
Avacta Group Plc Announces Board Appointments	06/06	CI
Avacta Group Plc Auditor Raises 'Going Concern' Doubt	06/06	CI
Avacta Group plc Announces Changes to Its Board, Effective Date Is April 30, 2025	29/04	CI
Avacta Therapeutics Presents Data from Lead Pre\|Cision® Candidate Fap-Dox At the 2025 Aacr Annual Meeting	28/04	CI
Avacta Therapeutics Issues Shares for Bond Repayment	23/04	MT
Avacta Group Says Ava6103 Phase 1 Trial To Begin Q1 2026	31/03	RE
Avacta Therapeutics Finalizes UK Diagnostics Unit Sale	25/03	MT
Duo-Med Group Belgium completed the acquisition of Launch Diagnostics Holdings Limited from Avacta Group Plc.	25/03	CI
Avacta Group Plc - Special Call	14/03
Avacta sells Launch Diagnostics; reports "promising" efficacy data	07/03	AN